Genmab — Februar 2016
-
Rigtigt Sukkeralf - en løbende indkomst kan finansiere en stor del af købesummen. Måske det hele hvis Darzalex og Arzerra (i MS) går så godt som vi håber
-
Måske har Gilead konstateret dette i forbindelse med deres testning af teknologien. De har jo cash til at købe. Så Mcjean, hvis Gilead selv har konstateret det du siger.......
-
Den pris er da ok for mit vedkommende
-
CHMP anbefaler udvidelse af label for Zydelig (Idelalisib) så den også omfatter kombi med Arzerra http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003843/WC500202365.pdf
-
Er der nogen som kan svare på denne her?
-
-
-
Fra link: We view Genmab / Janssen Biotech’s daratumumab (Darzalex
) as the most exciting new drug approved in 2015 – daratumumab, already granted Breakthrough Designation by the FDA, generated positive Phase II data in double refractory multiple myeloma in February demonstrating an impressive 29.2% overall response rate. The drug was filed with the FDA in July and approved approximately four months later. Darzalex is a major new option for patients and will be one of the key drug launches to f -
Tak Sukker.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind